Copley Shareholders Approve 12-Month Extension; 12.9M Shares Redeemed for $137M
COPL is trading near its 52-week low of $10.014 (6.2% above the low) on elevated volume (2.8× avg).
Summary
Shareholders approved the 12-month extension to November 2, 2027, with $200,000 per monthly extension funded by a $2.4 million unsecured, non-interest-bearing promissory note issued to the sponsor that matures at the earlier of a business combination closing or liquidation. The vote came with heavy redemptions: 12,889,720 Class A shares cashed out at about $10.63, roughly $137.1 million, leaving only about $46.2 million in trust and 4,550,280 Class A shares outstanding. That is a severe shrink of the deal vehicle — the trust is now a fraction of its original size, which sharply limits the size of any target Copley can take public. The first $200,000 drawdown extends the deadline to December 2, 2026. This follows the October 13 termination of the Ignite Proteomics merger and the October 30 adjournment of the vote, so the company is now starting from scratch on a much smaller pool of capital.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Copley issued a $2.4 million unsecured, non-interest-bearing promissory note to its sponsor, maturing at the earlier of a business combination closing or liquidation, with $200,000 drawn for the first extension.
At the time of this announcement, COPL was trading at $10.63 on NYSE in the Finance sector, with a market capitalization of approximately $191.6M. The 52-week trading range was $10.01 to $10.69. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.